Davidson Investment Advisors Grows Stock Position in Becton, Dickinson and Company $BDX

by · The Cerbat Gem

Davidson Investment Advisors increased its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 2.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,876 shares of the medical instruments supplier’s stock after acquiring an additional 2,946 shares during the period. Davidson Investment Advisors’ holdings in Becton, Dickinson and Company were worth $20,565,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. RiverGlades Family Offices LLC purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth approximately $344,000. B. Riley Wealth Advisors Inc. purchased a new stake in Becton, Dickinson and Company in the 2nd quarter worth approximately $983,000. Covea Finance increased its stake in shares of Becton, Dickinson and Company by 10.7% during the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock valued at $14,758,000 after buying an additional 7,610 shares during the period. Finally, Hutchinson Financial Advisors INC bought a new position in shares of Becton, Dickinson and Company during the second quarter valued at approximately $1,024,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on BDX. Piper Sandler cut their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Finally, Jefferies Financial Group upped their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $205.64.

Check Out Our Latest Report on BDX

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $194.73 on Friday. The company has a 50 day simple moving average of $191.03 and a two-hundred day simple moving average of $186.94. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The company has a market capitalization of $55.48 billion, a price-to-earnings ratio of 33.40, a P/E/G ratio of 1.79 and a beta of 0.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were paid a $1.05 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 629 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total transaction of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. This trade represents a 4.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 1,052 shares of company stock worth $201,235. Corporate insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).